Effect of low-molecular-weight heparin on potassium homeostasis

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue 3, 2002, Pages 107-110

  Abdel Raheem, Majdi M ^a   Potti, Anil ^a,b   Tadros, Sherine ^a   Koka, Vijay ^a   Hanekom, David ^a   Fraiman, Genise ^b   Danielson, Byron D ^b  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b Fargo VA Medical Center   (United States)

Author keywords

Adverse effect; Hyperkalemia; Low molecular weight heparin; Transtubular potassium gradient

Indexed keywords

CREATININE; ENOXAPARIN; HEPARIN; POTASSIUM; ALDOSTERONE; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; HUMAN; KIDNEY FUNCTION; MALE; METABOLIC ACTIVATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SERUM OSMOLALITY; THROMBOSIS PREVENTION; URINE OSMOLALITY; WILCOXON SIGNED RANKS TEST; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HOMEOSTASIS; HYPERKALEMIA; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; ORTHOPEDIC SURGERY; OSMOLARITY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; URINE; VEIN THROMBOSIS; ZONA GLOMERULOSA;

AGED; AGED, 80 AND OVER; ALDOSTERONE; CREATININE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOMEOSTASIS; HUMANS; HYPERKALEMIA; KIDNEY TUBULES; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; OSMOLAR CONCENTRATION; POSTOPERATIVE COMPLICATIONS; POTASSIUM; VENOUS THROMBOSIS; ZONA GLOMERULOSA;

EID: 0036579988     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065208     Document Type: Article

References (9)

1. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L: Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108 (suppl):258S-275S.
2. Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98:575-586.
3. Halperin ML, Goldstein MB: Fluid, Electrolyte, and Acid-Base Physiology: A Problem-Based Approach, ed 3.Philadelphia, Saunders, 1998.
4. West ML, Marsden PA, Richardson RM, Zettle RM, Halperin ML: New clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab 1986;12:234-238.
5. DuBose TD Jr: Hyperkalemic hyperchloremic metabolic acidosis: Pathophysiologic insights. Kidney Int 1997;51:591-602.
6. Canova CR, Fischler MP, Reinhart WH: Effect of low-molecular-weight heparin on serum potassium. Lancet 1997;349:1447-1448.
7. Levesque H, Verdier S, Cailleux N, et al: Low molecular weight heparins and hypoaldosteronism. BMJ 1990;300:1437-1438.
8. Wong KS, Kay R: Low-molecular-weight heparin and serum potassium. Lancet 1997;350:664.
9. Marcelli JM, Lalau JD, Abourachid H, Quiret JC, Quichaud J: Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res 1989;21:402.